What are the survival rates for locally advanced Kidney Cancer

Survival Rates for Locally Advanced Kidney Cancer

I appreciate your question about survival outcomes. Let me explain what we know about locally advanced kidney cancer and the important context around survival statistics.

What "Locally Advanced" Means

Locally advanced kidney cancer typically refers to Stage III disease — tumors that have grown beyond the kidney itself but haven't spread to distant organs. This might include:

• Tumors extending into the renal vein or inferior vena cava (the large vein returning blood to the heart)
• Cancer that has spread to nearby lymph nodes
• Tumors that are large or have invaded surrounding tissues

Why Survival Statistics Are Complex

Here's what's important to understand: survival rates for kidney cancer vary significantly based on several factors, and the NCCN Guidelines emphasize that no single number applies to everyone. Your specific outcome depends on:

• Histology type (clear cell vs. non-clear cell)
• Grade (how aggressive the cancer cells appear)
• Whether you receive surgery (nephrectomy/kidney removal)
• Whether you receive adjuvant therapy (additional treatment after surgery)
• Your overall health and performance status
• Prognostic risk factors (using tools like IMDC or MSKCC criteria)

What the Evidence Shows

According to NCCN Guidelines for Kidney Cancer, for patients with high-risk, localized or locally advanced clear cell RCC who undergo nephrectomy:

Adjuvant Pembrolizumab (immunotherapy) showed benefit in the KEYNOTE-564 trial:

• 77.3% of patients were disease-free at 24 months with pembrolizumab
• 68.1% of patients were disease-free at 24 months with placebo
• At 30-month follow-up, these benefits were sustained

This means pembrolizumab after surgery reduced the risk of recurrence or death by approximately 32% compared to observation alone.

Important Context About These Numbers

The NCCN Guidelines note that:

• Median overall survival (OS) had not been reached at the time of reporting — meaning more than half of patients were still alive at the time data was analyzed
• These are disease-free survival rates (staying cancer-free), not overall survival
• Individual outcomes vary considerably

Treatment Approach for Locally Advanced Disease

According to NCCN Guidelines, the standard approach typically includes:

1. Surgery first (radical or partial nephrectomy when feasible)
2. Adjuvant therapy consideration for high-risk patients:
   • Pembrolizumab (preferred for clear cell histology) — Category 1 recommendation
   • TKI therapy (sunitinib, pazopanib, axitinib) — though results are mixed
   • Surveillance (careful monitoring without immediate treatment)

Questions to Ask Your Oncologist

Since survival statistics are highly individualized, these questions will help you understand YOUR specific situation:

1. What is my specific stage, grade, and histology type? (This determines which survival data applies to you)
2. What are my prognostic risk factors? (Using IMDC or MSKCC criteria)
3. Do you recommend adjuvant therapy after surgery, and if so, which type?
4. What does the surveillance plan look like if I choose observation?
5. What are realistic outcomes for someone with my specific tumor characteristics?

Key Takeaway

Rather than focusing on a single "survival rate," it's more helpful to understand that:

• Modern treatments (especially immunotherapy like pembrolizumab) have improved outcomes for locally advanced kidney cancer
• Your individual prognosis depends on multiple factors your oncologist can assess
• Treatment decisions should be based on YOUR specific tumor characteristics and overall health

According to the NCCN Guidelines, the approach to locally advanced kidney cancer has evolved significantly, with newer immunotherapy options showing promise in extending disease-free survival.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.